MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...

neura.edu.au Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative ... with cortical hyperexcitability being an early feature in sporadic forms of ALS and preceding the ...

The former Bison player was diagnosed with the disease at age 34. He has reunited with a former teammate, coach John Griffin ...

targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Relapsing-remitting multiple sclerosis is a type of multiple sclerosis in which you experience relapses of the disease with periods of remission occurring in between. Relapsing-remitting multiple ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Multiple sclerosis (MS) in its end stages involves disabling and life threatening effects. Several home adaptations and palliative care are available and can improve survival, mobility ...

With the hold lifted, Amylyx can begin screening and enrolling for its Phase 1 LUMINA trial, which will test AMX0114 in ALS ...